The Mayo Clinic Cancer Center SPORE in Prostate Cancer comprises five Mayo investigator-initiated research projects, and four core resources constructed around a theme of prostate cancer and consolidated by an Administrative Core. The SPORE also contains Career Development and Developmental Research Programs. The Administrative Core supports the operational structure of this SPORE. It will provide coordination of the research projects, scientific cores, and developmental programs (Developmental Research Program, Career Development Program) of the SPORE. It will also serve to enhance communication between SPORE investigators and facilitate all SPORE operations and interactions. The Administrative Core will be responsible for coordinating the SPORE Executive Committee and the Advisory Council. Dr. Donald Tindall will serve as Director of the Administrative Core, and Dr Brian Davis will serve as Co- Director. The Administrative Core will support SPORE activities by: (1) providing leadership, organizational support, and financial management for SPORE investigators;(2) coordinating monthly scientific meetings of SPORE investigators, and the ongoing scientific review of SPORE research projects and cores;(3) reviewing progress of the SPORE full and developmental projects;(4) providing for information transfer to the scientific community via professional and public means;(5) providing the structure for nurturing collaborations to facilitate and expand prostate cancer research;and, (6) acting as liaison with leadership of the other Prostate SPOREs and the NCI SPORE Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA091956-10
Application #
8128732
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2013-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
10
Fiscal Year
2010
Total Cost
$201,435
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Guerrico, Anatilde Gonzalez; Hillman, David; Karnes, Jeffery et al. (2017) Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. J Circ Biomark 6:1849454417720151
Hearn, Jason W D; AbuAli, Ghada; Reichard, Chad A et al. (2016) HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol 17:1435-1444
Spratt, Daniel E; Evans, Michael J; Davis, Brian J et al. (2015) Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res 75:4688-96
Lu, Ji; Lonergan, Peter E; Nacusi, Lucas P et al. (2015) The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol 193:690-8
Urban, Matthew W; Wang, Chenyi; Alizad, Azra et al. (2015) Complex background suppression for vibro-acoustography images. Ultrasonics 56:456-72
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Alshalalfa, Mohammed; Crisan, Anamaria; Vergara, Ismael A et al. (2015) Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int 116:556-67
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Ahmed, Kamran A; Davis, Brian J; Mynderse, Lance A et al. (2014) Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol 9:171
Wu, Qiang; Kohli, Manish; Bergen 3rd, H Robert et al. (2014) Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther 13:1067-77

Showing the most recent 10 out of 206 publications